公开(公告)号：US20070026067A1

公开(公告)日：2007-02-01

申请号：US11495111

申请日：2006-07-28

申请人： Noymi Yam ,  Nipun Davar ,  Gayatri Sathyan ,  Suneel Gupta

发明人： Noymi Yam ,  Nipun Davar ,  Gayatri Sathyan ,  Suneel Gupta

IPC分类号： A61K9/22 ,  A61K31/519 ,  A61K31/42

CPC分类号： A61K31/519 ,  A61K9/0004 ,  A61K9/4891 ,  A61K31/42

摘要： Disclosed are dosage forms including a controlled release dosing structure; and a liquid formulation contained within the controlled release dosing structure; wherein the liquid formulation comprises a benzisoxazole derivative and a liquid carrier. Also disclosed are methods of making and using such dosage forms.

摘要翻译： 公开了包括控释剂量结构的剂型; 和包含在控释剂量结构内的液体制剂; 其中液体制剂包含苯并异恶唑衍生物和液体载体。 还公开了制备和使用这些剂型的方法。

公开(公告)号：US20050208132A1

公开(公告)日：2005-09-22

申请号：US11051060

申请日：2005-02-04

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K31/42 ,  A61K9/22

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US20120283275A1

公开(公告)日：2012-11-08

申请号：US13467761

申请日：2012-05-09

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/519 ,  A61P25/18

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US20110195981A1

公开(公告)日：2011-08-11

申请号：US13012490

申请日：2011-01-24

申请人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

发明人： Gayatri Sathyan ,  Suneel Gupta ,  Noymi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff

IPC分类号： A61K31/519 ,  A61P25/18

CPC分类号： A61K9/0004 ,  A61K31/519

摘要： Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.

摘要翻译： 公开了包含苯并异恶唑衍生物的剂型和方法。 更具体地，公开了苯甲异恶唑衍生物的剂型，方法和新用途，其显着降低或基本上消除了当给予患者时苯并异恶唑衍生物的某些副作用。

公开(公告)号：US20050232995A1

公开(公告)日：2005-10-20

申请号：US11051165

申请日：2005-02-04

申请人： Nyomi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel Gupta ,  Gayatri Sathyan

发明人： Nyomi Yam ,  Iran Reyes ,  Nipun Davar ,  Atul Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel Gupta ,  Gayatri Sathyan

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61K9/24

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US20090221621A1

公开(公告)日：2009-09-03

申请号：US12084396

申请日：2006-10-31

申请人： Gayatri Sathyan ,  Nipun Davar

发明人： Gayatri Sathyan ,  Nipun Davar

IPC分类号： A61K31/485 ,  A61P25/04

CPC分类号： A61K9/0004 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2086 ,  A61K31/485 ,  A61K47/10

摘要： Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol.

摘要翻译： 公开了持续释放给予阿片样物质的方法，所述阿片样物质包括但不限于氢吗啡酮和羟考酮，其在与含水醇共摄取时表现出改进的性质。

公开(公告)号：US20090202631A1

公开(公告)日：2009-08-13

申请号：US12428422

申请日：2009-04-22

申请人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

发明人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

IPC分类号： A61K31/519 ,  A61K9/20

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US09393192B2

公开(公告)日：2016-07-19

申请号：US12428422

申请日：2009-04-22

申请人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

发明人： Nyomi V. Yam ,  Iran Reyes ,  Nipun Davar ,  Atul D. Ayer ,  Julie Lee ,  Sonya Seroff ,  Suneel K. Gupta ,  Gayatri Sathyan

IPC分类号： A61K9/22 ,  A61K9/00 ,  A61K31/506 ,  A61K31/519

CPC分类号： A61K9/0004 ,  A61K9/0053 ,  A61K9/2086 ,  A61K9/209 ,  A61K31/506 ,  A61K31/519

摘要： Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

摘要翻译： 提供了用于提供帕培酮或利培酮的基本上升释放速率的剂型和方法。 当每天施用一次时，持续释放剂型提供治疗有效的平均稳态血浆普利培酮或利培酮浓度。 这种每天一次的给药方案导致每24小时内出现一次峰值血浆普利培酮或利培酮浓度。 此外，剂量给药后的较晚时间，峰值血浆普利培酮或利培酮浓度发生在比立即释放剂型给药帕立哌酮或利培酮后出现的峰值血浆普利培酮或利培酮浓度更小的程度。

公开(公告)号：US20050260268A1

公开(公告)日：2005-11-24

申请号：US10949900

申请日：2004-09-24

申请人： Nishit Modi ,  Suneel Gupta ,  Nipun Davar ,  Sonya Seroff

发明人： Nishit Modi ,  Suneel Gupta ,  Nipun Davar ,  Sonya Seroff

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/36 ,  A61K31/5517

CPC分类号： A61K31/5517 ,  A61K9/0004 ,  A61K9/2086

摘要： A dosage form for delivery of alprazolam is described. The sustained release dosage form provides via once-a-day dosing a therapeutically effective average steady-state plasma alprazolam concentration, where the maximum attained plasma concentration is achieved more than about 14 hours after administration. The slow, sustained release reduces side effects such as sedation and abuse potential.

摘要翻译： 描述了用于递送阿普唑仑的剂型。 持续释放剂型通过每天一次给药治疗有效的平均稳态血浆阿普唑仑浓度，其中在给药后超过约14小时达到最大达到的血浆浓度。 缓慢持续释放可减少诸如镇静和滥用潜力的副作用。

公开(公告)号：US20100266682A1

公开(公告)日：2010-10-21

申请号：US12764489

申请日：2010-04-21

申请人： Nipun Davar ,  Pauly Kavalakatt ,  Indiran Pather ,  Sangita Ghosh

发明人： Nipun Davar ,  Pauly Kavalakatt ,  Indiran Pather ,  Sangita Ghosh

IPC分类号： A61K9/14 ,  A61K31/437 ,  A61K9/20 ,  A61K9/48 ,  A61P25/20 ,  A61K31/46

CPC分类号： A61K9/14 ,  A61K9/0031 ,  A61K9/0036 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/437 ,  A61K31/4748 ,  A61K47/10

摘要： Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively.

摘要翻译： 描述了具有基本上覆盖至少一种碳酸盐颗粒的由一层聚乙二醇涂覆的至少一种碳酸颗粒的非泡腾药物组合物。 还描述了组合物，其中组合物包括弱碱性治疗剂，具有至少一种由一层聚乙二醇涂覆的碳酸颗粒的第一pH调节剂和第二pH调节剂。 弱碱性治疗剂可以是但不限于唑吡旦或东莨菪碱。 组合物包括唑吡旦和东莨菪碱分别用于治疗失眠和抑郁症。